Corbus Pharmaceuticals (NASDAQ: CRBP ) perks up 3% premarket on light volume in response to longer term data on lenabasum in mid-stage studies in systemic sclerosis (SSc) and dermatomyositis (DM). The results are being presented at EULAR in Madrid. More news on: Corbus Pharma…